WASHINGTON, April 20, 2018 /PRNewswire/ -- The
Antimicrobials Working Group (AWG) today announced that thirteen of
its member companies will present data from their clinical and
research programs at the annual meeting of the European Congress of
Clinical Microbiology and Infectious Diseases (ECCMID 2018) to be
held April 21 - 24 in Madrid, Spain.
ECCMID is an annual scientific meeting that brings together the
leading experts in the fields of clinical microbiology, infectious
disease and infection control from across the globe to present and
discuss the latest developments in the laboratory and in the clinic
to advance research in a wide array of infectious diseases.
"AWG is proud to share that data from our member companies
covering a vast swath of infectious disease topics will be
presented at ECCMID 2018," said Jeffrey
Stein, Ph.D., president and chief executive officer of
Cidara Therapeutics and Chairman of the AWG. "Representatives from
AWG companies will be participating in over 70 different oral
sessions and poster presentations showcasing developments in
innovative antifungal and antibacterial therapies, in addition to
progress related to therapeutic antibodies, new diagnostic tools,
and more."
The following AWG member companies will be presenting at ECCMID
2018: Arsanis Inc. (NASDAQ: ASNS), Amplyx Pharmaceuticals, Cidara
Therapeutics, Inc. (NASDAQ:CDTX), ContraFect Corporation
(NASDAQ:CFRX), Iterum Therapeutics Ltd., Melinta Therapeutics, Inc.
(NASDAQ:MLNT), Motif Bio plc (AIM/NASDAQ:MTFB), Nabriva
Therapeutics Plc (NASDAQ:NBRV), Paratek Pharmaceuticals, Inc.
(NASDAQ:PRTK), SCYNEXIS, Inc. (NASDAQ: SCYX), Spero Therapeutics,
Inc. (NASDAQ:SPRO), T2 Biosystems, Inc. (NASDAQ:TTOO) and
Theravance Biopharma, Inc. (NASDAQ:TBPH).
For more information on AWG member company presentations and
access to specific abstracts, please visit:
http://www.antimicrobialsworkinggroup.org/eccmid-2018/ .
About The Antimicrobials Working Group
AWG was founded in 2012 with the vision of utilizing collective
power to improve the regulatory, investment, and commercial
environment for emerging infectious disease companies. Today, AWG
is comprised of seventeen antimicrobials and diagnostic device
companies: Amplyx Pharmaceuticals, Aridis Pharmaceuticals, Arsanis
Inc., Cidara Therapeutics Inc., ContraFect Corporation, Iterum
Therapeutics Ltd., Melinta Therapeutics Inc., Motif Bio PLC,
Nabriva Therapeutics US Inc., Paratek Pharmaceuticals Inc.,
SCYNEXIS Inc., Spero Therapeutics, Inc., T2 Biosystems Inc.,
Theravance Biopharma U.S. Inc., Viamet, Vical Incorporated, and
Zavante Therapeutics Inc.
For more information, visit:
www.antimicrobialsworkinggroup.org
About The Conafay Group
The Conafay Group, led by Stephen R.
Conafay, Principal, is a life-sciences government relations
firm based in Washington D.C. that
serves as Washington counsel and
coalition manager for AWG.
For more information, visit: www.conafaygroup.com
View original
content:http://www.prnewswire.com/news-releases/antimicrobials-working-group-highlights-member-company-participation-at-the-28th-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid-300633669.html
SOURCE Antimicrobials Working Group (AWG)